Saudi Journal of Kidney Diseases and Transplantation (Jan 2020)

A case of renal and splenic LECT 2 amyloidosis: A recently recognized cause of renal and systemic amyloidosis

  • Michael Shye,
  • Anthony Sisk,
  • Carl Schulze,
  • Marina Barsoum,
  • Mira Mikhail,
  • Farid Arman,
  • Anjay Rastogi,
  • Ramy M Hanna

DOI
https://doi.org/10.4103/1319-2442.284027
Journal volume & issue
Vol. 31, no. 2
pp. 508 – 514

Abstract

Read online

Amyloidosis has traditionally been of a few defined varieties, most commonly including light-chain amyloidosis (AL amyloidosis) and secondary amyloidosis due to chronic inflammation (AA amyloidosis). Apolipoprotein A-I/A-II cystatin C, gelsolin, lysozyme, fibrinogen alpha chain, beta 2 microglobulin, and transthyretin familial amyloidosis represent rarer but reported varieties. Ten years ago, the first reports linked leukocyte chemotactic factor 2 (LECT2) amyloidosis as a pathological agent identified as a novel class of amyloid-generating protein. Epidemiology suggested that this was a new cause of amyloidosis that is especially common in Hispanic patients and somewhat common among patients from the Middle East-North Africa (MENA) region. We report a case of splenic and renal LECT 2 amyloidosis in a 62-year- old Hispanic male with diabetes mellitus. After an unremarkable serological workup, LECT 2 amyloidosis was diagnosed on renal biopsy. The case presentation is reviewed as a typical presentation, and the literature is reviewed regarding this newly reported entity, resulting in infiltrative renal amyloidosis and chronic renal disease.